Granted Patent
B2
US 7,576,219 · App. 11/374,034 · Granted Aug 18, 2009
Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
Claims (2)
1. A crystalline S-omeprazole strontium tetrahydrate of the following formula (I):
which has the X-ray powder diffraction spectrum showing peaks having I/I o values of at least 3% at 2θ±0.2 of 5.6, 11.1, 13.5, 14.8, 16.2, 17.5, 18.0, 20.1, 20.4, 21.2, 22.2, 24.5, 25.2, 26.3, 27.5, 29.8, 31.1, 32.8 and 36.5.
Assignments (3)
CHANGE OF NAME
Recorded Aug 3, 2012
From: HANMI HOLDINGS CO., LTD.
To: HANMI SCIENCE CO., LTD.
Reel/Frame 028722/0332 →
CHANGE OF NAME
Recorded Feb 18, 2011
From: HANMI PHARM. CO., LTD.
To: HANMI HOLDINGS CO., LTD.
Reel/Frame 025839/0380 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 14, 2006
From: HA, TAE HEE; OH, HEE SOOK; KIM, WON JEOUNG; PARK, CHANG HEE; KIM, EUN-YOUNG; KIM, YOUNG HOON; SUH, KWEE HYUN; LEE, GWAN SUN
To: HANMI PHARM. CO., LTD.
Reel/Frame 017688/0128 →